| Symbol | AKTS |
|---|---|
| Name | AKTIS ONCOLOGY, INC. |
| Sector | UTILITIES |
| Region | North America |
| Industry | Telecommunications Equipment |
| Address | 9805 NORTHCROSS CENTER COURT,SUITE A, HUNTERSVILLE, North Carolina, 28078, United States |
| Telephone | +1 704 997-5735 |
| Fax | — |
| — | |
| Website | https://www.aktisoncology.com/ |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Akoustis is a high-tech BAW RF filter solutions company that is pioneering next-generation materials science to address the market requirements for improved RF filters - targeting higher bandwidth higher operating frequencies and higher output power compared to incumbent polycrystalline BAW technology deployed today. The Company utilizes its proprietary XBAW single-crystal BAW manufacturing process to produce bulk acoustic wave RF filters for mobile and other wireless markets which facilitate signal acquisition and accelerate band performance between the antenna and digital back end. Superior performance is driven by the significant advances of high-purity single crystal piezoelectric materials and the resonator-filter process technology which drives electro-mechanical coupling and translates to wide filter bandwidth. Additional info from NASDAQ: |
Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Read moreGormley Glenn 🟢 acquired 37.9K shares (1 derivative) of Aktis Oncology, Inc. (AKTS) at $18.09 Transaction Date: Apr 15, 2026 | Filing ID: 159028
Read more(85% Positive) AKTIS ONCOLOGY, INC. (AKTS) Announces Clinical Development Update
Read moreNew Form 3 - Aktis Oncology, Inc. <b>Filed:</b> 2026-04-16 <b>AccNo:</b> 0001193125-26-158968 <b>Size:</b> 22 KB
Read moreAktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
Read moreAktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
Read moreNew Form 10-K - Aktis Oncology, Inc. <b>Filed:</b> 2026-03-30 <b>AccNo:</b> 0001193125-26-131748 <b>Size:</b> 7 MB
Read more